×
News Home

Should You Add Lexaria Bioscience Corp (LEXX) Stock to Your Portfolio Friday?

Friday, January 14, 2022 03:38 PM | InvestorsObserver Analysts
Should You Add Lexaria Bioscience Corp (LEXX) Stock to Your Portfolio Friday?

A rating of 22 puts Lexaria Bioscience Corp (LEXX) near the top of the Consumer Defensive sector according to InvestorsObserver. Lexaria Bioscience Corp's score of 22 means that it ranks higher than 22% of stocks in the sector. In addition, its overall score of 38 ranks it higher than 38% of all stocks.

Overall Score - 38
LEXX has an Overall Score of 38. Find out what this means to you and get the rest of the rankings on LEXX!

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 38 means the stock is more attractive than 38 percent of stocks. These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Lexaria Bioscience Corp Stock Today?

Lexaria Bioscience Corp (LEXX) stock is up 3.85% while the S&P 500 has fallen -0.06% as of 3:36 PM on Friday, Jan 14. LEXX has risen $0.17 from the previous closing price of $4.41 on volume of 33,692 shares. Over the past year the S&P 500 has gained 22.68% while LEXX has risen 2.92%. LEXX lost -$1.26 per share the over the last 12 months. Click Here to get the full Stock Report for Lexaria Bioscience Corp stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App